Department of Cardiology, Herlev-Gentofte Hospital University of Copenhagen, Copenhagen, Denmark.
The Danish Heart Foundation, Copenhagen, Denmark.
Clin J Am Soc Nephrol. 2017 Nov 7;12(11):1814-1822. doi: 10.2215/CJN.02320317. Epub 2017 Oct 3.
Endocarditis is a serious complication in patients treated with RRT. The study aimed to examine incidence and risk factors of endocarditis in patients with ESRD.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The Danish National Registry on Regular Dialysis and Transplantation contains data on all Danish patients receiving renal replacement (hemodialysis, peritoneal dialysis, or kidney transplantation) for ESRD. Incidence of endocarditis was estimated for each RRT modality. Independent risk factors of endocarditis were identified in multivariable Cox regression models.
From January 1st, 1996 to December 31st, 2012, 10,612 patients (mean age 63 years, 36% female) initiated RRT (7233 hemodialysis, 3056 peritoneal dialysis, 323 pre-emptive kidney transplantation). Endocarditis developed in 267 (2.5%); of these 31 (12%) underwent valve surgery. The overall incidence of endocarditis was 627 per 100,000 person-years in patients receiving RRT. Incidence was higher in patients receiving hemodialysis compared with those receiving peritoneal dialysis or kidney transplantation (1092 per 100,000 person-years, 212 per 100,000 person-years, and 85 per 100,000 person-years, respectively). Adjusted hazard ratios for endocarditis in patients receiving hemodialysis were 5.46 (95% confidence interval [95% CI], 3.28 to 9.10) and 0.41 (95% CI, 0.18 to 0.91) for kidney-transplanted recipients, respectively, as compared with patients in peritoneal dialysis. The incidence of endocarditis in hemodialysis recipients with central venous catheters was more than two-fold higher as compared with those with arteriovenous fistulas. Overall mortality, subsequent to endocarditis, was 22% in-hospital and 51% at 1 year. The first 6 months in RRT, aortic valve disease, and previous endocarditis were identified as significant risk factors of endocarditis.
Patients receiving RRT have a high incidence of endocarditis, in particular during hemodialysis treatment using central venous catheters. The first 6 months in RRT, aortic valve disease, and previous endocarditis are significant risk factors for developing endocarditis.
心内膜炎是接受肾脏替代治疗(RRT)的患者的严重并发症。本研究旨在研究终末期肾病患者的心内膜炎发生率和危险因素。
设计、设置、参与者和测量:丹麦国家定期透析和移植登记处包含所有接受肾脏替代治疗(血液透析、腹膜透析或肾移植)治疗终末期肾病的丹麦患者的数据。估计了每种 RRT 方式的心内膜炎发生率。使用多变量 Cox 回归模型确定心内膜炎的独立危险因素。
从 1996 年 1 月 1 日至 2012 年 12 月 31 日,10612 名患者(平均年龄 63 岁,36%为女性)开始接受 RRT(7233 名血液透析患者、3056 名腹膜透析患者、323 名预防性肾移植患者)。267 名患者(2.5%)发生心内膜炎;其中 31 名(12%)接受了瓣膜手术。接受 RRT 的患者的心内膜炎总发生率为每 100000 人年 627 例。与接受腹膜透析或肾移植的患者相比,接受血液透析的患者心内膜炎发生率更高(每 100000 人年分别为 1092 例、212 例和 85 例)。与腹膜透析患者相比,接受血液透析的患者发生心内膜炎的调整后危险比分别为 5.46(95%置信区间[95%CI],3.28 至 9.10)和 0.41(95%CI,0.18 至 0.91)。与动静脉瘘患者相比,接受血液透析且使用中心静脉导管的患者心内膜炎发生率高出两倍以上。心内膜炎发生后,院内总死亡率为 22%,1 年死亡率为 51%。RRT 的前 6 个月、主动脉瓣疾病和既往心内膜炎被确定为心内膜炎的显著危险因素。
接受 RRT 的患者心内膜炎发生率较高,尤其是在使用中心静脉导管进行血液透析治疗期间。RRT 的前 6 个月、主动脉瓣疾病和既往心内膜炎是发生心内膜炎的显著危险因素。